Helping Your Patients Find Novolog During Supply Disruptions

When a patient calls your office because their pharmacy can't fill their Novolog (Insulin Aspart) prescription, the clock is ticking. For patients with type 1 diabetes or insulin-dependent type 2 diabetes, even a short gap in mealtime insulin can have serious consequences — from dangerous hyperglycemia to diabetic ketoacidosis.

This guide gives your clinical team a practical playbook for helping patients locate Novolog in stock, identify alternatives when needed, and navigate the cost and access landscape in 2026.

Current Novolog Availability

As of early 2026, Novolog (Insulin Aspart) is generally available from Novo Nordisk, but supply remains uneven at the pharmacy level:

• FlexPen and FlexTouch pens: Widely available at most retail and mail-order pharmacies.
• Vials (10 mL): Intermittently available. Some pharmacies and regions continue to experience periodic stock-outs.
• PenFill cartridges: Limited availability at specialty pharmacies.
• Unbranded Insulin Aspart: Discontinued as of December 31, 2025. No longer available.

The supply picture can change week to week, so real-time data is essential. For current availability, direct your team to Medfinder for Providers.

Why Patients Can't Find Novolog

Understanding the root causes helps you communicate effectively with patients and plan ahead:

• Unbranded product discontinuation: The end of Novo Nordisk's unbranded Insulin Aspart shifted significant volume back to brand Novolog, straining supply chains.
• Regional demand spikes: Some markets have higher diabetes prevalence and greater competition for insulin inventory.
• Pharmacy ordering patterns: Chain pharmacies may under-order during periods of supply uncertainty, creating artificial scarcity at the store level even when manufacturer supply is adequate.
• Insulin pump users: Patients using continuous subcutaneous insulin infusion (CSII) typically need higher volumes of rapid-acting insulin, and they have fewer options for switching to alternatives without pump compatibility verification.

What Providers Can Do: 5 Practical Steps

Step 1: Verify Availability Before the Patient Leaves

When writing or renewing a Novolog prescription, have your staff check availability at the patient's pharmacy before they leave your office. A quick call or a check on Medfinder for Providers can save the patient a wasted trip and valuable time.

Step 2: Prescribe with Presentation Flexibility

If your patient's insurance covers both vials and pens, specify in the prescription that either presentation is acceptable. Vials have been more prone to stock-outs than pens in 2026. By allowing the pharmacy to dispense what's in stock, you reduce the chance of a fill failure.

Consider writing: "Novolog 100 units/mL, 10 mL vial OR FlexPen 5-pack, dispense whichever is in stock."

Step 3: Have a Pre-Approved Alternative Ready

For patients at high risk of supply disruptions — those with type 1 diabetes, insulin pump users, or patients in underserved areas — consider documenting a pre-approved alternative in their chart. This allows your staff to quickly process a prescription change without requiring a new appointment.

Recommended alternatives:

• Humalog (Insulin Lispro): 1:1 dose conversion for most patients. Widely available.
• Fiasp (Insulin Aspart): Same active ingredient as Novolog with faster onset. Straightforward switch.
• Admelog (Insulin Lispro): Biosimilar to Humalog. Often preferred by payers for lower cost.
• Apidra (Insulin Glulisine): Less commonly stocked but clinically comparable.

For more detail on these options, see our provider briefing on the Novolog shortage for prescribers.

Step 4: Connect Patients with Cost Resources

Access barriers are often financial as much as supply-related. Ensure your team knows about:

• Novo Nordisk Savings Card: $35 per 30-day supply for commercially insured patients.
• Novo Nordisk PAP: Free medication for eligible uninsured patients via NovoCare.com.
• Medicare $35 cap: All Medicare Part D plans cap insulin copays at $35/month under the Inflation Reduction Act.
• GoodRx / SingleCare coupons: Can reduce cash prices to $74-$100 per vial for uninsured or underinsured patients.

For a comprehensive cost resource, see How to Help Patients Save Money on Novolog: A Provider's Guide.

Step 5: Educate Patients on Self-Advocacy

Empower your patients with the tools and knowledge to navigate supply issues independently:

• Show them how to use Medfinder to check pharmacy stock.
• Encourage them to build relationships with independent pharmacies.
• Advise them to refill early and maintain a small buffer supply when possible.
• Share the NovoCare phone number: 1-866-310-7549.

Therapeutic Alternatives in Detail

When switching a patient from Novolog to an alternative rapid-acting insulin, keep these clinical considerations in mind:

• Dose conversion: Generally 1:1 between Novolog, Humalog, Fiasp, and Admelog. Individual patient response may vary.
• Pump compatibility: Not all insulin pump manufacturers approve all rapid-acting insulins for use in their devices. Verify compatibility before switching pump patients. Novolog, Humalog, and Fiasp are approved for most major pump systems.
• Monitoring: Recommend increased self-monitoring of blood glucose (SMBG) or continuous glucose monitor (CGM) review for the first 1-2 weeks after any insulin switch.
• Patient education: Ensure patients understand the new product's packaging, pen operation (if applicable), and any differences in dosing timing. Fiasp, for example, can be dosed at the start of a meal or up to 20 minutes after — a notable difference from Novolog's 5-10 minute pre-meal recommendation.

Workflow Tips for Your Practice

Incorporating shortage management into your workflow can reduce disruption for both your team and your patients:

• Flag high-risk patients: Identify patients on Novolog who would be most affected by a supply disruption (type 1 diabetes, single-insulin regimen, limited pharmacy access) and proactively document alternatives.
• Empower your MA or nurse: Train medical assistants and nurses to check availability, initiate prescription changes for pre-approved alternatives, and connect patients with savings programs.
• Batch prescription updates: When formulary changes or supply issues affect multiple patients, process prescription updates as a batch rather than reactively.
• Use secure messaging: Send proactive messages through your patient portal about supply updates and what patients should do if they can't fill their Novolog prescription.

Final Thoughts

Helping patients navigate insulin shortages is an increasingly important part of diabetes care. By staying informed about Novolog availability, maintaining pre-approved alternatives, and connecting patients with cost resources, you can minimize the clinical impact of supply disruptions.

Bookmark Medfinder for Providers as a quick-reference tool for your clinical team, and review our patient-facing Novolog shortage update to share with your patients.